medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 4

<< Back Next >>

Med Int Mex 2022; 38 (4)

D dimer concentration variation as predictor of mortality in patients with COVID-19

Ontiveros-Austria JL, González-Rodríguez KT, Reyes-Rodríguez EA, Vicencio-Lomelí E, Sánchez-Sánchez JM, Velázquez-Guevara BA, Andoney-Mayén JV, Valdez-Vargas G, Hernández-Patiño EJ, Aranda-Hernández YS, Rodríguez-López RG

Language: Spanish
References: 24
Page: 760-766
PDF size: 226.86 Kb.


ABSTRACT

Objective: To evaluate the D dimer levels after the admission of patients with COVID- 19 and to stablish cut-off points that are associated with more complications.
Materials and Methods: Prospective study with inpatients with severity criteria that compared the D dimer levels at admission and 48 hours later; mean D dimer concentrations were evaluated and cut-off points were stablished.
Results: Considering D dimer 48 hours after admission, patients that did not survive had mean levels of 5380 ng/mL versus 1811.3 ng/mL among those that survived (p ‹ 0.005); a cut-off point of 1725 ng/mL was stablished that predicted mortality with sensitivity of 85.7%, specificity of 63%, and negative predictive value of 89.4%. In the group of patients that required invasive mechanical ventilation, mean D dimer was 4672.2 ng/mL versus 1652.6 ng/mL in those who did not need it (p ‹ 0.001) and a cut-off point of 1770 ng/mL was calculated which predicted invasive mechanical ventilation with sensitivity of 84.6%, specificity of 63%, and negative predictive value of 89.4%.
Conclusions: D dimer concentrations after 48 hours of admission can discard the development of complications, so its determination may be useful for determining the adverse evolution risk.


REFERENCES

  1. Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patientsinfected with 2019 novel coronavirus in Wuhan, China.Lancet 2020; 395: 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.

  2. Gu J, Gong E, Zhang B, Zheng J, et al. Multiple organ infectionand the pathogenesis of SARS. J Exp Med 2005;202: 415-424. https://doi.org/10.1084%2Fjem.20050828.

  3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesisof coronavirus disease (COVID-19) outbreak.J Autoimmun 2020; 109: 1024-1033. doi: 10.1016/j.jaut.2020.102433.

  4. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathyof coronavirus disease 2019. Crit Care Med 2020; XX: 1358-1364. doi: 10.1097/CCM.0000000000004458.

  5. Gruppo collaborativo – Terapia COVID-19 LombardiaCoordinamento. Vademecum per la cura delle personecon malattia da COVI-19. Simit 2020: 1-15.

  6. Chandel A, Patolia S, Looby M, Dalton HJ, et al. Associationof D-dimer and fibrinogen magnitude with hypercoagulabilityby thromboelastography in severe COVID-19 2. medRxiv2020. DOI: 10.1101/2020.07.27.20162842.

  7. Bikdeli B, Madhavan MV, Jiménez D, Chuich T, et al.COVID-19 and thrombotic or thromboembolic disease:implications for prevention, antithrombotic therapy, andfollow-up: JACC State-of-the-Art Review. J Am Coll Cardiol2020; 75: 2950-2973. doi: 10.1016/j.jacc.2020.04.031.

  8. Whyte CS, Morrow GB, Mitchell JL, Chowdary P, MutchNJ. Fibrinolytic abnormalities in acute respiratory distresssyndrome (ARDS) and versatility of thrombolytic drugs totreat COVID-19. J Thromb Haemost 2020; 18: 1548-1555.doi: 10.1111/jth.14872.

  9. Linkins LA, Takach Lapner S. Review of D-dimer testing:Good, Bad, and Ugly. Int J Lab Hematol 2017; 39: 98-103.doi: 10.1111/ijlh.12665.

  10. Connors JM, Levy JH. COVID-19 and its implications forthrombosis and anticoagulation. Blood 2020; 135: 2033-2040. doi: 10.1182/blood.2020006000.

  11. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, et al.Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. BrJ Haematol 2020; 189: 846-847. doi: 10.1111/bjh.16727.

  12. Yu B, Li X, Chen J, Ouyang M, et al. Evaluation of variation inD-dimer levels among COVID-19 and bacterial pneumonia:a retrospective analysis. J Thromb Thrombolysis 2020; 50:548-557. doi: 10.1007/s11239-020-02171-y.

  13. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parametersare associated with poor prognosis in patients withnovel coronavirus pneumonia. J Thromb Haemost 2020;18: 844-847. doi: 10.1111/jth.14768.

  14. Group RC. Dexamethasone in hospitalized patients withCovid-19 — Preliminary report. N Engl J Med 2020. DOI:10.1056/NEJMoa2021436.

  15. Naymagon L, Zubizarreta N, Feld J, van Gerwen M, et al.Admission D-dimer levels, D-dimer trends, and outcomes inCOVID-19. Thromb Res 2020; 196: 99-105. doi: 10.1016/j.thromres.2020.08.032.

  16. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The roleof biomarkers in diagnosis of COVID-19 – A systematicreview. Life Sci 2020; 254: 1177-1188. doi: 10.1016/j.lfs.2020.117788.

  17. Yu H, Qin C, Chen M, Wang W, Tian D. D-dimer level isassociated with the severity of COVID-19. Thromb. Res2020; 195: 219-225. doi: 10.1016/j.thromres.2020.07.047.

  18. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, et al. Venousand arterial thromboembolic complications in COVID-19 patientsadmitted to an academic hospital in Milan, Italy. ThrombRes 2020; 191: 9-14. doi: 10.1016/j.thromres.2020.04.024.

  19. Thachil J, Tang N, Gando S, Falanga A, et al. ISTH interimguidance on recognition and management of coagulopathyin COVID-19. J Thromb Haemost 2020; 18: 1023-1026. doi:10.1111/jth.14810.

  20. Simadibrata DM, Lubis AM. D-dimer levels on admissionand all-cause mortality risk in COVID-19 patients: A meta-Analysis. Epidemiol Infect 2020; 148: 1-7. doi: 10.1017/S0950268820002022.

  21. Yao Y, Cao J, Wang Q, Shi Q, et al. D-dimer as a biomarkerfor disease severity and mortality in COVID-19 patients: Acase control study. J Intensive Care 2020; 8: 1-11. https://doi.org/10.1186/s40560-020-00466-z.

  22. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L,Parra-Virto A, et al. Incidence of asymptomatic deep veinthrombosis in patients with COVID-19 pneumonia andelevated D-dimer levels. Thromb Res 2020; 192: 23-26.doi: 10.1016/j.thromres.2020.05.018.

  23. Choi JJ, Wehmeyer GT, Li HA, Alshak MN, et al. D-dimercut-off points and risk of venous thromboembolism inadult hospitalized patients with COVID-19. Thromb Res2020; 196: 318-321. doi: 10.1016/j.thromres.2020.09.022.

  24. Lippi G, Favaloro EJ. D-dimer is associated with severity ofcoronavirus disease 2019: A pooled analysis. Thromb Haemost2020; 120: 876-878. doi: 10.1055/s-0040-1709650.




2020     |     www.medigraphic.com